ATAI News and Press, ATAI Life Sciences N.V. From 08/15/22

Atai Life Sciences N.V. (ATAI) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer ...

Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Atai completed a company-wide cost optimization initiative and an extensive pipeline revie...

ATAI Life Sciences press release ( NASDAQ: ATAI ): Q2 GAAP EPS of -$0.24 misses by $0.01 . Cash, cash equivalents and short-term investments totaled $312.5 million as of June 30, 2022, compared to $362.3 million as of December 31, 2021. For further details see: ...

- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections -&#x...

- Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments - Flexible draw availability provides optionality to optimize liquidity and capital struc...

COMPASS Pathways is developing a psychedelic drug to treat many mental illnesses. The drug appears to be safe and effective for a wide range of mental health problems. If the drug gets authorized and approved, it will be the only available pharmacological treatment for millions an...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of “magic...

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and busi...

Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, was featured in a recent analysis report that discusses... To read the full report and view the infographic, please visit https://ibn.fm/SHjWL ...

On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan's 2018 book, "How to Change Your Mind," is one of Netflix's most-watched shows. ...